Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC50292A in MTAP-deleted Advanced or Metastatic Solid Tumors
NCT07071090Phase 1Recruiting
- Sponsor
- HeraNova Lifesciences
- Start
- Jun 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DC50292A in solid tumor, sponsored by HeraNova Lifesciences. Primary endpoint: Number of Participants With Adverse Events at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
DC50292A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07071090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071090.